Related Experiment Video
Updated: Aug 12, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
New Drugs for the Treatment of HIV Infection
1Division of International Medicine and Infectious Disease, Department of Medicine, Weill Medical College of Cornell University, Box 566, 525 East 68th Street, New York, NY 10021, USA. rgulick@med.cornell.edu
Abstract:
Despite the availability of 15 approved drugs for the treatment of HIV infection, issues of convenience, tolerability, and antiretroviral activity make the continued development of newer drugs important. New drugs in clinical development represent both existing classes of antiretroviral agents--reverse transcriptase inhibitors (eg, diaminopurine dioxolane), nonnucleoside reverse transcriptase inhibitors (eg, capravirine), and protease inhibitors (eg, tipranavir and BMS-232632)--and newer classes of antiretroviral agents, such as nucleotide analogue reverse transcriptase inhibitors (eg, tenofovir) and fusion inhibitors (eg, pentafuside). Newer drugs may offer improvements over existing agents by having simpler dosing schedules (once or twice daily), better tolerability, or improved virologic activity against wild-type or resistant virus. Continued advancements in HIV treatment will stem from ongoing development of antiretroviral drugs.
More Related Videos
12:03Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy
Published on: September 5, 2016
10:29Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Related Concept Videos
Retrovirus Life Cycles
FDA Approved Drugs: Changes to Approved Drugs
Inhibitors of Viral Protein Synthesis
Inhibitors Of Virion Release
Antiviral Nucleoside Inhibitors
Inhibitors of Virion Maturation and Assembly